Bill Nygren
Oakmark Select Fund
Bill Nygren Regeneron Pharmaceuticals Inc stake
total: 60
Oakmark Select Fund REGN trades
- Total transactions:
- 9
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Reduced:
- 6
- Held since:
- 2019 Q3
- Held for:
- 11 quarters
- Latest activity:
- 2022 Q2
According to 2026 Q1 report, Bill Nygren doesn't hold any Regeneron Pharmaceuticals Inc (REGN) shares. To date, the estimated cost basis is nearly $366.99 for "buy" trades and estimated average "sell" price is $583.19. Oakmark Select Fund first purchased REGN in 2019 Q3, initially acquiring 620,000 shares. Since the initial investment in Regeneron Pharmaceuticals Inc (REGN), Oakmark Select Fund has made 8 more transactions.
When did Bill Nygren sell Regeneron Pharmaceuticals Inc (REGN)?
Bill Nygren sold off the entire Regeneron Pharmaceuticals Inc (REGN) position in 2022 Q2.
When did Bill Nygren buy Regeneron Pharmaceuticals Inc (REGN)?
Bill Nygren first invested in Regeneron Pharmaceuticals Inc (REGN) in 2019 Q3 at the reported quarter-end price of $277.40 per share.
What's the cost basis of Oakmark Select Fund's REGN stake?
The estimated cost basis for Regeneron Pharmaceuticals Inc (REGN) stake is around $366.99 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $366.99
- Weighted AVG sell price:
- $583.19
Bill Nygren's historical trades in Regeneron Pharmaceuticals Inc
9 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2022 Q2
|
0.00%
|
0
|
$698.42
|
|
-100% (-224,000)
|
-2.93%
|
|
2022 Q1
|
2.93%
|
224,000
|
$698.42
|
$156,446,080
|
-22.76% (-66,000)
|
-0.82%
|
|
2021 Q3
|
3.23%
|
290,000
|
$605.18
|
$175,502,200
|
-6.45% (-20,000)
|
-0.23%
|
|
2021 Q2
|
3.34%
|
310,000
|
$558.54
|
$173,147,400
|
+1,450.00% (+290,000)
|
+3.12%
|
|
2020 Q4
|
0.23%
|
$483.11
|
-83.92% (-104,400)
|
|||
|
2020 Q3
|
2.05%
|
$559.78
|
-59.13% (-180,000)
|
|||
|
2020 Q2
|
5.31%
|
$623.65
|
-20.71% (-79,491)
|
|||
|
2020 Q1
|
5.80%
|
$488.29
|
-38.08% (-236,109)
|
|||
|
2019 Q3
|
3.86%
|
$277.40
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.